The purpose of this study is to test the safety and efficacy of GW679769 and paroxetine in subjects with Social Anxiety Disorder
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
242
The primary outcome measure will be the change from baseline in the Liebowitz Social Anxiety Scale (LSAS)
Secondary outcome measures include the change from baseline in the following scales: the Clinical Global Impression-Global Improvement, the Clinical Global Impression -Severity of Illness, and the Sheehan Disability Scale.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Beverly Hills, California, United States
GSK Investigational Site
Burbank, California, United States
GSK Investigational Site
Jacksonville, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
North Miami, Florida, United States
GSK Investigational Site
Orlando, Florida, United States
GSK Investigational Site
Smyrna, Georgia, United States
GSK Investigational Site
Oakbrook Terrace, Illinois, United States
GSK Investigational Site
Rockville, Maryland, United States
GSK Investigational Site
New York, New York, United States
...and 17 more locations